GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Respiratory syncytial virus (RSV), or human respiratory syncytial ... These findings have been implemented by GSK and Pfizer to utilize the pre-F RSV protein as their immunogen for vaccine research.

PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk Strategic ...

Tom, a GSK patient advocate and 70-year-old grandfather ... One of the available vaccinations is AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted), an FDA-approved vaccine used to prevent ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...